Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III study of Cannabidiol in prevention of acute graft versus host disease (GVHD)

Next Previous
Trial Profile

A phase III study of Cannabidiol in prevention of acute graft versus host disease (GVHD)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 14 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Graft-versus-host disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Claritas Pharmaceuticals

    • Most Recent Events

    • 11 Sep 2019 According to an Kalytera Therapeutics media release, the company announced that it is updating the terms of its private placement previously announced on August 21, 2019. The Company proposes to raise up to approximately CDN $1.5 million (USD $1.14 million) pursuant to the Private Placement.
    • 21 Aug 2019 According to a Kalytera Therapeutics media release, the company intends to raise up to approximately CDN $1.5 million (USD $1.13 million) in a private placement. The proceeds will be utilized to fund preparatory work for initiation of phase 3 study in prevention of acute graft versus host disease.
    • 05 Oct 2018 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top